Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors

被引:4
作者
Nakagawa, Ryunosuke [1 ]
Iwamoto, Hiroaki [1 ]
Makino, Tomoyuki [2 ]
Kadomoto, Suguru [1 ]
Yaegashi, Hiroshi [1 ]
Iijima, Masashi [1 ]
Kawaguchi, Shohei [1 ]
Nohara, Takahiro [1 ]
Shigehara, Kazuyoshi [1 ]
Izumi, Kouji [1 ]
Kadono, Yoshifumi [1 ]
Mizokami, Atsushi [1 ]
机构
[1] Kanazawa Univ, Dept Integrat Canc Therapy & Urol, Grad Sch Med Sci, Kanazawa, Ishikawa, Japan
[2] Ishikawa Prefectural Cent Hosp, Dept Urol, Kanazawa, Ishikawa, Japan
来源
FRONTIERS IN ONCOLOGY | 2022年 / 11卷
关键词
bleomycin; etoposide; and cisplatin (BEP) treatment; germ cell tumor; neutropenia; granulocyte colony-stimulating factor; pegfilgrastim; COLONY-STIMULATING FACTOR; INDUCED FEBRILE NEUTROPENIA; SINGLE-ADMINISTRATION PEGFILGRASTIM; DOUBLE-BLIND; PRIMARY PROPHYLAXIS; DAILY FILGRASTIM; BREAST-CANCER; LUNG-CANCER; CHEMOTHERAPY; MULTICENTER;
D O I
10.3389/fonc.2021.770067
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It has been reported that chemotherapy drugs and granulocyte colony-stimulating factor (G-CSF) administered on the same day can aggravate neutropenia. In the present study, we investigated the safety of pegfilgrastim during bleomycin, etoposide, and cisplatin (BEP) therapy. This single-center retrospective study, including 137 cycles of BEP therapy for germ cell tumors between January 2008 and April 2021, investigated safety. Short-acting G-CSF was used for 84 cycles and pegfilgrastim was used for 53 cycles. In the pegfilgrastim group, neutrophil count at nadir was significantly higher than in the G-CSF group (median 1,650/mu l and 680/mu l, respectively). The incidence of grade 3-4 neutropenia was significantly higher and the duration longer in the G-CSF group. Also, there was no significant difference in the incidence of febrile neutropenia. In conclusion, concomitant use of pegfilgrastim during BEP therapy did not increase neutropenia and was effective in terms of safety.
引用
收藏
页数:7
相关论文
共 35 条
  • [1] 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
    Aapro, M. S.
    Bohlius, J.
    Cameron, D. A.
    Dal Lago, Lissandra
    Donnelly, J. Peter
    Kearney, N.
    Lyman, G. H.
    Pettengell, R.
    Tjan-Heijnen, V. C.
    Walewski, J.
    Weber, Damien C.
    Zielinski, C.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 (01) : 8 - 32
  • [2] Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations
    Aapro, Matti
    Boccia, Ralph
    Leonard, Robert
    Camps, Carlos
    Campone, Mario
    Choquet, Sylvain
    Danova, Marco
    Glaspy, John
    Hus, Iwona
    Link, Hartmut
    Sliwa, Thamer
    Tesch, Hans
    Valero, Vicente
    [J]. SUPPORTIVE CARE IN CANCER, 2017, 25 (11) : 3295 - 3304
  • [3] Differential Sensitivity of Lipegfilgrastim and Pegfilgrastim to Neutrophil Elastase Correlates With Differences in Clinical Pharmacokinetic Profile
    Abdolzade-Bavil, Afsaneh
    von Kerczek, Aaron
    Cooksey, Bridget A.
    Kaufman, Thomas
    Krasney, Philip A.
    Pukac, Laurie
    Goerlach, Matthias
    Lammerich, Andreas
    Scheckermann, Christian
    Allgaier, Hermann
    Shen, Wenyan David
    Liu, Patrick M.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (02) : 186 - 194
  • [4] Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis
    Azoulay, E
    Herigault, S
    Levame, M
    Brochard, L
    Schlemmer, B
    Harf, A
    Delclaux, C
    [J]. CRITICAL CARE MEDICINE, 2003, 31 (05) : 1442 - 1448
  • [5] Benguerfi S., 2018, BMJ CASE REP, V2018
  • [6] BLUM RH, 1973, CANCER, V31, P903, DOI 10.1002/1097-0142(197304)31:4<903::AID-CNCR2820310422>3.0.CO
  • [7] 2-N
  • [8] Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies
    Burris, Howard A., III
    Belani, Chandra P.
    Kaufman, Peter A.
    Gordon, Alan N.
    Schwartzberg, Lee S.
    Paroly, Warren S.
    Shahin, Seta
    Dreiling, Lyndah
    Saven, Alan
    [J]. JOURNAL OF ONCOLOGY PRACTICE, 2010, 6 (03) : 133 - 140
  • [9] Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignanciesbendamustine and G-CSF support
    Cerchione, Claudio
    De Renzo, Amalia
    Nappi, Davide
    Di Perna, Maria
    Della Pepa, Roberta
    Pugliese, Novella
    Catalano, Lucio
    Pane, Fabrizio
    Picardi, Marco
    [J]. SUPPORTIVE CARE IN CANCER, 2019, 27 (05) : 1587 - 1588
  • [10] Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience
    Cerchione, Claudio
    De Renzo, Amalia
    Di Perna, Maria
    Della Pepa, Roberta
    Pugliese, Novella
    Catalano, Lucio
    Pane, Fabrizio
    Picardi, Marco
    [J]. SUPPORTIVE CARE IN CANCER, 2017, 25 (03) : 839 - 845